Form 4: BioMarin Director Countouriotis Receives Stock Grant
SEC Form 4 Filing
Director Athena Countouriotis acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock through a restricted stock unit grant.
Summary
- On May 20, 2025, Athena Countouriotis, a director of BioMarin Pharmaceutical Inc., acquired 6,650 shares of common stock.
- The acquisition was a result of a restricted stock unit grant.
- Following the transaction, Countouriotis directly owns 13,550 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the sentiment is neutral. It simply reports a stock grant to a director.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers.
Stakeholder Impact
- The stock grant to a director may have a minor positive impact on shareholder sentiment, reflecting confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Athena Countouriotis acquired 6,650 shares of BioMarin common stock through a restricted stock unit grant. |
| 05/22/2025 | Date of signature by Attorney-in-Fact. |
Keywords
BioMarin, Director, Countouriotis, Stock Grant, Form 4, Beneficial Ownership, BMRN, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.